Umbrella Study for Analysis of Data Related to Patients With Cancer
Launched by TEMPUS AI · Aug 28, 2023
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Umbrella Study for Analysis of Data Related to Patients with Cancer, is focused on gathering and analyzing information from the medical records of patients who have been diagnosed with cancer. The goal is to use this information to answer important research questions and create a strong collection of real-world data that can help improve cancer care. This study is currently open for new participants, and anyone diagnosed with cancer can potentially join, as there are no specific exclusions based on age or gender.
If you or a family member are eligible, you can expect to contribute to research that may benefit future cancer patients. The study does not involve any new treatments or procedures; it simply uses existing medical records to gather valuable insights. Your participation would help researchers better understand cancer and improve care for others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects must be diagnosed with cancer
- • Medical records available to meet cohort requirements
- Exclusion Criteria:
- • - None
About Tempus Ai
Tempus AI is a leading technology company at the forefront of precision medicine, specializing in harnessing the power of data and artificial intelligence to advance cancer care. By integrating clinical and molecular data with advanced analytics, Tempus AI empowers healthcare providers to make informed, evidence-based decisions that enhance patient outcomes. With a commitment to innovation and collaboration, Tempus AI drives the development of targeted therapies and personalized treatment plans, positioning itself as a pivotal force in the evolution of oncology and clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sioux Falls, South Dakota, United States
Peoria, Illinois, United States
Long Beach, California, United States
Fairhaven, Massachusetts, United States
Honolulu, Hawaii, United States
Indianapolis, Indiana, United States
Rolling Meadows, Illinois, United States
Maumee, Ohio, United States
Fountain Valley, California, United States
Fargo, Maryland, United States
Fargo, North Dakota, United States
Jacksonville, Florida, United States
Patients applied
Trial Officials
Virginia Rhodes, MD
Study Director
Tempus AI, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported